A Prospective Cohort Study of ITB Treatment for HSP
Intrathecal Baclofen for the Management of Hereditary Spastic Paraparesis: a Prospective Cohort Study
Shanghai 6th People's Hospital
50 participants
Jan 1, 2025
OBSERVATIONAL
Conditions
Summary
The investigators conduct a prospective cohort study to explore the treatment effectiveness of continuous infusion of intrathecal baclofen (ITB) for hereditary spastic paraplegia (HSP) in China, delve into the optimal timing for starting treatment, and investigate the response differences among different subtypes. The ultimate goal is to provide clinical evidence and guidance for the application of ITB in treating HSP in China, as well as improve the life expectancy and quality of life for HSP patients. The main questions it aims to answer are: 1. Changes in gait and motor function, as well as spasticity levels, compared to pre-surgery and control group after ITB surgery. 2. Changes in quality of life, pain, psychological and emotional status, and cognition compared to pre-surgery and control group after ITB surgery. 3. Complications following ITB surgery. 4. Impact of ITB surgery on the occurrence and progression of skeletal deformities. 5. Subgroup analysis: comparing surgical outcomes between different genotypes and between simple versus complex types. 6. Determine the optimal timing for ITB intervention.
Eligibility
Inclusion Criteria4
- Patients meet the clinical and genetic diagnostic criteria of hereditary spastic paraplegia (HSP);
- Age: 14 to 70 years old
- Modified Ashworth Score for lower limbs: ≥2 joints with muscle tone ≥grade 3
- Patients are willing to participate in clinical trials and able to understand and comply with the research program
Exclusion Criteria6
- Patients are allergic to the baclofen
- Other neurological diseases likely affecting the evaluation of study treatment
- Other medical conditions such as: heart disease, tumor, blood disease, liver disease, kidney disease, etc. in the past 1 year
- Pregnancy or lactating women or subjects who are unable to use appropriate contraception during the trial
- Participating in another study drug trial and used the investigational drug in the past 30 days
- Subjects have poor compliance or other factors that are not suitable for participating in the clinical trial
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06844734